

**TDMS No.** 97008-06  
**Test Type:** CHRONIC  
**Route:** RESPIRATORY EXPOSURE WHOLE BODY  
**Species/Strain:** MICE/B6C3F1

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

PROPARGYL ALCOHOL

**CAS Number:** 107-19-7

**Date Report Requested:** 07/11/2006

**Time Report Requested:** 13:06:48

**First Dose M/F:** 09/17/01 / 09/17/01

**Lab:** BNW

F1\_M3

**C Number:** C97008

**Lock Date:** 08/16/2004

**Cage Range:** 1 - 9999

**Date Range:** 1-JAN-1940 to 17-SEP-2040

**Reasons For Removal:** ALL

**Removal Date Range:** JAN /1 /1940 - SEP /17 /2040

**Treatment Groups:** Include 1 CONTROL

Include 2 CONTROL

Include 3 8 PPM

Include 4 8 PPM

Include 5 16 PPM

Include 6 16 PPM

Include 7 32 PPM

Include 8 32 PPM

TDMS No. 97008-06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

PROPARGYL ALCOHOL

CAS Number: 107-19-7

Date Report Requested: 07/11/2006

Time Report Requested: 13:06:48

First Dose M/F: 09/17/01 / 09/17/01

Lab: BNW

## SUMMARY OF STATISTICALLY SIGNIFICANT ( $P \leq .05$ ) RESULTS IN THE ANALYSIS OF PROPARGYL ALCOHOL

### MALE MICE

#### Organ

Eye: Cornea

Liver

Nose

Nose: Glands, Respiratory Epithelium

Nose: Olfactory Epithelium

Nose: Respiratory Epithelium

Nose: Turbinate

Thyroid Gland: Follicular Cell

### FEMALE MICE

#### Organ

Eye

Eye: Cornea

Kidney

Liver

Nose

Nose: Glands, Respiratory Epithelium

Nose: Olfactory Epithelium

Nose: Respiratory Epithelium

Nose: Turbinate

Pituitary Gland: Pars Distalis

Uterus: Endometrium

#### Morphology

Inflammation Chronic

Clear Cell Focus

Inflammation

Hyperplasia

Atrophy

Metaplasia Respiratory

Hyperplasia

Metaplasia

Atrophy

Hyperplasia

#### Morphology

Cataract

Inflammation Chronic

Amyloid Deposition

Eosinophilic Focus

Hematopoietic Cell Proliferation

Inflammation

Hyperplasia

Atrophy

Metaplasia Respiratory

Hyperplasia

Metaplasia

Atrophy

Angiectasis

Hyperplasia

Hyperplasia Cystic

TDMS No. 97008-06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 PROPARGYL ALCOHOL  
 CAS Number: 107-19-7

Date Report Requested: 07/11/2006  
 Time Report Requested: 13:06:48  
 First Dose M/F: 09/17/01 / 09/17/01  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Adrenal Cortex  
 Hyperplasia**

**LESION RATES**

OVERALL (a)	12/49 (24%)	16/50 (32%)	9/49 (18%)	13/50 (26%)
POLY-3 RATE (b)	12/43.62	16/47.97	9/46.46	13/47.12
POLY-3 PERCENT (g)	27.5%	33.4%	19.4%	27.6%
TERMINAL (d)	12/37 (32%)	15/43 (35%)	8/40 (20%)	12/42 (29%)
FIRST INCIDENCE	729 (T)	572	565	667

**STATISTICAL TESTS**

LIFE TABLE	P=0.380N	P=0.414	P=0.241N	P=0.540N
POLY 3	P=0.411N	P=0.353	P=0.253N	P=0.589
POLY 1.5	P=0.429N	P=0.310	P=0.276N	P=0.562
POLY 6	P=0.391N	P=0.405	P=0.231N	P=0.563N
LOGISTIC REGRESSION	P=0.405N	P=0.391	P=0.245N	P=0.550N
COCH-ARM / FISHERS	P=0.461N	P=0.272	P=0.312N	P=0.523
ORDER RESTRICTED	P=0.360N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.376N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Adrenal Cortex  
Hypertrophy**

**LESION RATES**

OVERALL (a)	24/49 (49%)	24/50 (48%)	22/49 (45%)	18/50 (36%)
POLY-3 RATE (b)	24/44.84	24/47.46	22/46.68	18/47.78
POLY-3 PERCENT (g)	53.5%	50.6%	47.1%	37.7%
TERMINAL (d)	21/37 (57%)	24/43 (56%)	19/40 (48%)	16/42 (38%)
FIRST INCIDENCE	550	729 (T)	565	505

**STATISTICAL TESTS**

LIFE TABLE	P=0.050N*	P=0.301N	P=0.295N	P=0.066N
POLY 3	P=0.062N	P=0.470N	P=0.342N	P=0.090N
POLY 1.5	P=0.071N	P=0.512N	P=0.371N	P=0.106N
POLY 6	P=0.053N	P=0.427N	P=0.317N	P=0.075N
LOGISTIC REGRESSION	P=0.062N	P=0.357N	P=0.314N	P=0.095N
COCH-ARM / FISHERS	P=0.093N	P=0.541N	P=0.420N	P=0.135N
ORDER RESTRICTED	P=0.094N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.097N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM
<b>Adrenal Medulla Hyperplasia</b>				
<b>LESION RATES</b>				
OVERALL (a)	2/47 (4%)	3/50 (6%)	0/49 (0%)	3/50 (6%)
POLY-3 RATE (b)	2/42.14	3/48.11	0/45.93	3/47.20
POLY-3 PERCENT (g)	4.8%	6.2%	0%	6.4%
TERMINAL (d)	1/36 (3%)	0/43 (0%)	0/40 (0%)	2/42 (5%)
FIRST INCIDENCE	639	572	---	641
<b>STATISTICAL TESTS</b>				
LIFE TABLE	P=0.532	P=0.560	P=0.226N	P=0.562
POLY 3	P=0.534	P=0.560	P=0.218N	P=0.551
POLY 1.5	P=0.529	P=0.544	P=0.222N	P=0.542
POLY 6	P=0.538	P=0.577	P=0.216N	P=0.562
LOGISTIC REGRESSION	P=0.496	P=0.525	P=0.243N	P=0.513
COCH-ARM / FISHERS	P=0.520	P=0.530	P=0.237N	P=0.530
ORDER RESTRICTED	P=0.429	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.445	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

Eye  
Cataract

**LESION RATES**

OVERALL (a)	0/49 (0%)	0/50 (0%)	1/48 (2%)	2/49 (4%)
POLY-3 RATE (b)	0/43.62	0/47.46	1/45.28	2/45.88
POLY-3 PERCENT (g)	0%	0%	2.2%	4.4%
TERMINAL (d)	0/37 (0%)	0/43 (0%)	1/40 (3%)	2/41 (5%)
FIRST INCIDENCE	---	---	729 (T)	729 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.074	(e)	P=0.516	P=0.261
POLY 3	P=0.072	(e)	P=0.507	P=0.249
POLY 1.5	P=0.071	(e)	P=0.503	P=0.244
POLY 6	P=0.073	(e)	P=0.512	P=0.254
LOGISTIC REGRESSION	(e)	(e)	P=0.516	P=0.261
COCH-ARM / FISHERS	P=0.069	(e)	P=0.495	P=0.247
ORDER RESTRICTED	P=0.081	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.093	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

Eye: Cornea  
Fibrosis

**LESION RATES**

OVERALL (a)	2/49 (4%)	0/50 (0%)	0/48 (0%)	2/49 (4%)
POLY-3 RATE (b)	2/43.62	0/47.46	0/45.28	2/46.08
POLY-3 PERCENT (g)	4.6%	0%	0%	4.3%
TERMINAL (d)	2/37 (5%)	0/43 (0%)	0/40 (0%)	1/41 (2%)
FIRST INCIDENCE	729 (T)	---	---	677

**STATISTICAL TESTS**

LIFE TABLE	P=0.518	P=0.206N	P=0.221N	P=0.654N
POLY 3	P=0.495	P=0.219N	P=0.229N	P=0.674N
POLY 1.5	P=0.497	P=0.226N	P=0.234N	P=0.682N
POLY 6	P=0.491	P=0.211N	P=0.224N	P=0.664N
LOGISTIC REGRESSION	P=0.506	(e)	(e)	P=0.677N
COCH-ARM / FISHERS	P=0.497	P=0.242N	P=0.253N	P=0.691N
ORDER RESTRICTED	P=0.248N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.263N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

Eye: Cornea  
Inflammation Chronic

**LESION RATES**

OVERALL (a)	1/49 (2%)	0/50 (0%)	5/48 (10%)	7/49 (14%)
POLY-3 RATE (b)	1/43.62	0/47.46	5/45.28	7/45.88
POLY-3 PERCENT (g)	2.3%	0%	11%	15.3%
TERMINAL (d)	1/37 (3%)	0/43 (0%)	5/40 (13%)	7/41 (17%)
FIRST INCIDENCE	729 (T)	---	729 (T)	729 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.003**	P=0.470N	P=0.121	P=0.044*
POLY 3	P=0.003**	P=0.483N	P=0.110	P=0.035*
POLY 1.5	P=0.002**	P=0.490N	P=0.105	P=0.033*
POLY 6	P=0.003**	P=0.476N	P=0.116	P=0.038*
LOGISTIC REGRESSION	P=0.003**	(e)	P=0.121	P=0.044*
COCH-ARM / FISHERS	P=0.003**	P=0.495N	P=0.097	P=0.030*
ORDER RESTRICTED	P=0.005**	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.004**	(e)	(e)	(e)



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

Eye: Cornea, Epithelium  
Hyperplasia

**LESION RATES**

OVERALL (a)	0/49 (0%)	0/50 (0%)	2/48 (4%)	0/49 (0%)
POLY-3 RATE (b)	0/43.62	0/47.46	2/45.28	0/45.88
POLY-3 PERCENT (g)	0%	0%	4.4%	0%
TERMINAL (d)	0/37 (0%)	0/43 (0%)	2/40 (5%)	0/41 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.608	(e)	P=0.256	(e)
POLY 3	P=0.609	(e)	P=0.246	(e)
POLY 1.5	P=0.604	(e)	P=0.240	(e)
POLY 6	P=0.615	(e)	P=0.251	(e)
LOGISTIC REGRESSION	(e)	(e)	P=0.256	(e)
COCH-ARM / FISHERS	P=0.593	(e)	P=0.242	(e)
ORDER RESTRICTED	P=0.254	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.269	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Harderian Gland  
Hyperplasia**

**LESION RATES**

OVERALL (a)	2/49 (4%)	5/50 (10%)	2/49 (4%)	3/50 (6%)
POLY-3 RATE (b)	2/44.19	5/47.46	2/45.93	3/47.00
POLY-3 PERCENT (g)	4.5%	10.5%	4.4%	6.4%
TERMINAL (d)	1/37 (3%)	5/43 (12%)	2/40 (5%)	2/42 (5%)
FIRST INCIDENCE	550	729 (T)	729 (T)	698

**STATISTICAL TESTS**

LIFE TABLE	P=0.540N	P=0.276	P=0.668N	P=0.545
POLY 3	P=0.552N	P=0.246	P=0.680N	P=0.528
POLY 1.5	P=0.560N	P=0.235	P=0.685N	P=0.520
POLY 6	P=0.543N	P=0.260	P=0.675N	P=0.538
LOGISTIC REGRESSION	P=0.564N	P=0.226	P=0.668	P=0.483
COCH-ARM / FISHERS	P=0.573N	P=0.226	P=0.691N	P=0.510
ORDER RESTRICTED	P=0.488	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.500	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Heart  
Cardiomyopathy**

**LESION RATES**

OVERALL (a)	5/50 (10%)	9/50 (18%)	8/50 (16%)	9/50 (18%)
POLY-3 RATE (b)	5/45.81	9/47.50	8/48.26	9/47.63
POLY-3 PERCENT (g)	10.9%	19%	16.6%	18.9%
TERMINAL (d)	3/37 (8%)	8/43 (19%)	2/40 (5%)	6/42 (14%)
FIRST INCIDENCE	493	719	565	641

**STATISTICAL TESTS**

LIFE TABLE	P=0.285	P=0.279	P=0.330	P=0.267
POLY 3	P=0.251	P=0.213	P=0.311	P=0.215
POLY 1.5	P=0.240	P=0.201	P=0.296	P=0.205
POLY 6	P=0.268	P=0.231	P=0.331	P=0.231
LOGISTIC REGRESSION	P=0.201	P=0.190	P=0.154	P=0.151
COCH-ARM / FISHERS	P=0.224	P=0.194	P=0.277	P=0.194
ORDER RESTRICTED	P=0.240	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.251	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

Heart: Artery  
Inflammation Chronic

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.46	0/47.46	0/46.58	0/46.88
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/37 (0%)	0/43 (0%)	0/40 (0%)	0/42 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

LIFE TABLE	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Islets, Pancreatic  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/49 (0%)	2/50 (4%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.62	2/47.46	0/45.93	0/46.88
POLY-3 PERCENT (g)	0%	4.2%	0%	0%
TERMINAL (d)	0/37 (0%)	2/43 (5%)	0/40 (0%)	0/42 (0%)
FIRST INCIDENCE	---	729 (T)	---	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.388N	P=0.272	(e)	(e)
POLY 3	P=0.382N	P=0.256	(e)	(e)
POLY 1.5	P=0.391N	P=0.249	(e)	(e)
POLY 6	P=0.372N	P=0.266	(e)	(e)
LOGISTIC REGRESSION	(e)	P=0.272	(e)	(e)
COCH-ARM / FISHERS	P=0.402N	P=0.253	(e)	(e)
ORDER RESTRICTED	P=0.251N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.266N	(e)	(e)	(e)

TDMS No. 97008-06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

PROPARGYL ALCOHOL

CAS Number: 107-19-7

Date Report Reqsted: 07/11/2006

Time Report Reqsted: 13:06:48

First Dose M/F: 09/17/01 / 09/17/01

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

Kidney  
Amyloid Deposition

LESION RATES

OVERALL (a)	0/49 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.62	0/47.46	0/46.58	0/46.88
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/37 (0%)	0/43 (0%)	0/40 (0%)	0/42 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

LIFE TABLE	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Kidney  
Cyst**

**LESION RATES**

OVERALL (a)	0/49 (0%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/43.62	1/47.46	2/46.58	0/46.88
POLY-3 PERCENT (g)	0%	2.1%	4.3%	0%
TERMINAL (d)	0/37 (0%)	1/43 (2%)	2/40 (5%)	0/42 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.595N	P=0.530	P=0.256	(e)
POLY 3	P=0.595N	P=0.517	P=0.252	(e)
POLY 1.5	P=0.601N	P=0.510	P=0.248	(e)
POLY 6	P=0.587N	P=0.524	P=0.255	(e)
LOGISTIC REGRESSION	(e)	P=0.530	P=0.256	(e)
COCH-ARM / FISHERS	P=0.612N	P=0.505	P=0.253	(e)
ORDER RESTRICTED	P=0.331N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.348N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Kidney  
Inflammation**

**LESION RATES**

OVERALL (a)	1/49 (2%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/43.82	2/47.97	1/46.93	0/46.88
POLY-3 PERCENT (g)	2.3%	4.2%	2.1%	0%
TERMINAL (d)	0/37 (0%)	1/43 (2%)	0/40 (0%)	0/42 (0%)
FIRST INCIDENCE	677	572	630	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.235N	P=0.546	P=0.740N	P=0.476N
POLY 3	P=0.233N	P=0.532	P=0.745N	P=0.487N
POLY 1.5	P=0.237N	P=0.519	P=0.749N	P=0.490N
POLY 6	P=0.229N	P=0.545	P=0.741N	P=0.482N
LOGISTIC REGRESSION	P=0.269N	P=0.510	P=0.725	P=0.515N
COCH-ARM / FISHERS	P=0.243N	P=0.508	P=0.747N	P=0.495N
ORDER RESTRICTED	P=0.232N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.245N	(e)	(e)	(e)

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Kidney  
Metaplasia Osseous**

**LESION RATES**

OVERALL (a)	3/49 (6%)	3/50 (6%)	4/50 (8%)	5/50 (10%)
POLY-3 RATE (b)	3/43.62	3/47.46	4/46.58	5/47.00
POLY-3 PERCENT (g)	6.9%	6.3%	8.6%	10.6%
TERMINAL (d)	3/37 (8%)	3/43 (7%)	4/40 (10%)	4/42 (10%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	698

**STATISTICAL TESTS**

LIFE TABLE	P=0.289	P=0.592N	P=0.543	P=0.428
POLY 3	P=0.274	P=0.623N	P=0.536	P=0.398
POLY 1.5	P=0.269	P=0.638N	P=0.526	P=0.386
POLY 6	P=0.281	P=0.604N	P=0.544	P=0.414
LOGISTIC REGRESSION	P=0.282	P=0.592N	P=0.543	P=0.419
COCH-ARM / FISHERS	P=0.255	P=0.651N	P=0.511	P=0.369
ORDER RESTRICTED	P=0.388	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.402	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Kidney  
Nephropathy**

**LESION RATES**

OVERALL (a)	46/49 (94%)	47/50 (94%)	47/50 (94%)	46/50 (92%)
POLY-3 RATE (b)	46/48.31	47/48.80	47/49.65	46/49.05
POLY-3 PERCENT (g)	95.2%	96.3%	94.7%	93.8%
TERMINAL (d)	35/37 (95%)	42/43 (98%)	38/40 (95%)	40/42 (95%)
FIRST INCIDENCE	440	572	493	499

**STATISTICAL TESTS**

LIFE TABLE	P=0.203N	P=0.148N	P=0.388N	P=0.170N
POLY 3	P=0.404N	P=0.597	P=0.636N	P=0.556N
POLY 1.5	P=0.380N	P=0.567	P=0.646N	P=0.532N
POLY 6	P=0.445N	P=0.613	P=0.643N	P=0.596N
LOGISTIC REGRESSION	P=0.302N	P=0.677	P=0.618N	P=0.411N
COCH-ARM / FISHERS	P=0.413N	P=0.651	P=0.651	P=0.511N
ORDER RESTRICTED	P=0.503N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.508N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Kidney: Pelvis  
Dilatation**

**LESION RATES**

OVERALL (a)	0/49 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.62	2/47.95	0/46.58	0/46.88
POLY-3 PERCENT (g)	0%	4.2%	0%	0%
TERMINAL (d)	0/37 (0%)	1/43 (2%)	0/40 (0%)	0/42 (0%)
FIRST INCIDENCE	---	583	---	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.394N	P=0.264	(e)	(e)
POLY 3	P=0.380N	P=0.259	(e)	(e)
POLY 1.5	P=0.390N	P=0.250	(e)	(e)
POLY 6	P=0.370N	P=0.269	(e)	(e)
LOGISTIC REGRESSION	P=0.424N	P=0.243	(e)	(e)
COCH-ARM / FISHERS	P=0.402N	P=0.253	(e)	(e)
ORDER RESTRICTED	P=0.253N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.268N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

Liver  
Basophilic Focus

**LESION RATES**

OVERALL (a)	5/49 (10%)	8/50 (16%)	5/49 (10%)	5/50 (10%)
POLY-3 RATE (b)	5/43.94	8/47.95	5/45.93	5/47.16
POLY-3 PERCENT (g)	11.4%	16.7%	10.9%	10.6%
TERMINAL (d)	4/37 (11%)	7/43 (16%)	5/40 (13%)	4/42 (10%)
FIRST INCIDENCE	639	583	729 (T)	653

**STATISTICAL TESTS**

LIFE TABLE	P=0.367N	P=0.373	P=0.584N	P=0.550N
POLY 3	P=0.386N	P=0.335	P=0.602N	P=0.585N
POLY 1.5	P=0.396N	P=0.311	P=0.612N	P=0.598N
POLY 6	P=0.375N	P=0.362	P=0.593N	P=0.570N
LOGISTIC REGRESSION	P=0.395N	P=0.306	P=0.588N	P=0.593N
COCH-ARM / FISHERS	P=0.416N	P=0.290	P=0.630N	P=0.617N
ORDER RESTRICTED	P=0.484N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.496N	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

Liver  
Clear Cell Focus

**LESION RATES**

OVERALL (a)	18/49 (37%)	11/50 (22%)	13/49 (27%)	4/50 (8%)
POLY-3 RATE (b)	18/43.62	11/47.97	13/45.93	4/46.88
POLY-3 PERCENT (g)	41.3%	22.9%	28.3%	8.5%
TERMINAL (d)	18/37 (49%)	10/43 (23%)	13/40 (33%)	4/42 (10%)
FIRST INCIDENCE	729 (T)	572	729 (T)	729 (T)

**STATISTICAL TESTS**

LIFE TABLE	P<0.001N**	P=0.032N*	P=0.114N	P<0.001N**
POLY 3	P<0.001N**	P=0.046N*	P=0.141N	P<0.001N**
POLY 1.5	P<0.001N**	P=0.061N	P=0.160N	P<0.001N**
POLY 6	P<0.001N**	P=0.032N*	P=0.122N	P<0.001N**
LOGISTIC REGRESSION	P<0.001N**	P=0.036N*	P=0.114N	P<0.001N**
COCH-ARM / FISHERS	P<0.001N**	P=0.082N	P=0.193N	P<0.001N**
ORDER RESTRICTED	P<0.001N**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001N**	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

Liver  
Eosinophilic Focus

**LESION RATES**

OVERALL (a)	3/49 (6%)	3/50 (6%)	2/49 (4%)	3/50 (6%)
POLY-3 RATE (b)	3/43.82	3/47.50	2/45.93	3/46.88
POLY-3 PERCENT (g)	6.9%	6.3%	4.4%	6.4%
TERMINAL (d)	2/37 (5%)	2/43 (5%)	2/40 (5%)	3/42 (7%)
FIRST INCIDENCE	677	719	729 (T)	729 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.521N	P=0.585N	P=0.465N	P=0.603N
POLY 3	P=0.542N	P=0.624N	P=0.479N	P=0.631N
POLY 1.5	P=0.546N	P=0.639N	P=0.487N	P=0.640N
POLY 6	P=0.539N	P=0.608N	P=0.471N	P=0.621N
LOGISTIC REGRESSION	P=0.530N	P=0.621N	P=0.471N	P=0.621N
COCH-ARM / FISHERS	P=0.556N	P=0.651N	P=0.500N	P=0.651N
ORDER RESTRICTED	P=0.602N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.609N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Liver  
Hematopoietic Cell Proliferation**

**LESION RATES**

OVERALL (a)	0/49 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.62	0/47.46	0/45.93	0/46.88
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/37 (0%)	0/43 (0%)	0/40 (0%)	0/42 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

LIFE TABLE	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

Liver  
Necrosis

**LESION RATES**

OVERALL (a)	3/49 (6%)	2/50 (4%)	2/49 (4%)	1/50 (2%)
POLY-3 RATE (b)	3/45.21	2/48.17	2/46.28	1/47.00
POLY-3 PERCENT (g)	6.6%	4.2%	4.3%	2.1%
TERMINAL (d)	0/37 (0%)	0/43 (0%)	1/40 (3%)	0/42 (0%)
FIRST INCIDENCE	440	572	633	698

**STATISTICAL TESTS**

LIFE TABLE	P=0.220N	P=0.466N	P=0.479N	P=0.286N
POLY 3	P=0.229N	P=0.471N	P=0.489N	P=0.292N
POLY 1.5	P=0.228N	P=0.483N	P=0.493N	P=0.295N
POLY 6	P=0.229N	P=0.457N	P=0.486N	P=0.288N
LOGISTIC REGRESSION	P=0.291N	P=0.456N	P=0.665	P=0.439N
COCH-ARM / FISHERS	P=0.228N	P=0.490N	P=0.500N	P=0.301N
ORDER RESTRICTED	P=0.230N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.240N	(e)	(e)	(e)

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

Liver  
Tension Lipidosis

**LESION RATES**

OVERALL (a)	1/49 (2%)	4/50 (8%)	3/49 (6%)	3/50 (6%)
POLY-3 RATE (b)	1/43.93	4/47.97	3/45.93	3/46.88
POLY-3 PERCENT (g)	2.3%	8.3%	6.5%	6.4%
TERMINAL (d)	0/37 (0%)	3/43 (7%)	3/40 (8%)	3/42 (7%)
FIRST INCIDENCE	642	572	729 (T)	729 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.394	P=0.225	P=0.332	P=0.352
POLY 3	P=0.387	P=0.207	P=0.321	P=0.329
POLY 1.5	P=0.379	P=0.196	P=0.316	P=0.323
POLY 6	P=0.395	P=0.220	P=0.326	P=0.336
LOGISTIC REGRESSION	P=0.365	P=0.182	P=0.311	P=0.318
COCH-ARM / FISHERS	P=0.364	P=0.187	P=0.309	P=0.316
ORDER RESTRICTED	P=0.269	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.283	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Lung  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.46	2/47.66	0/46.58	0/46.88
POLY-3 PERCENT (g)	0%	4.2%	0%	0%
TERMINAL (d)	0/37 (0%)	1/43 (2%)	0/40 (0%)	0/42 (0%)
FIRST INCIDENCE	---	677	---	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.392N	P=0.275	(e)	(e)
POLY 3	P=0.384N	P=0.253	(e)	(e)
POLY 1.5	P=0.393N	P=0.245	(e)	(e)
POLY 6	P=0.373N	P=0.263	(e)	(e)
LOGISTIC REGRESSION	P=0.406N	P=0.238	(e)	(e)
COCH-ARM / FISHERS	P=0.405N	P=0.247	(e)	(e)
ORDER RESTRICTED	P=0.251N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.265N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Lung: Alveolar Epithelium  
Hyperplasia**

**LESION RATES**

OVERALL (a)	4/50 (8%)	4/50 (8%)	5/50 (10%)	7/50 (14%)
POLY-3 RATE (b)	4/44.77	4/47.66	5/46.58	7/46.88
POLY-3 PERCENT (g)	8.9%	8.4%	10.7%	14.9%
TERMINAL (d)	3/37 (8%)	3/43 (7%)	5/40 (13%)	7/42 (17%)
FIRST INCIDENCE	642	677	729 (T)	729 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.208	P=0.558N	P=0.546	P=0.338
POLY 3	P=0.182	P=0.608N	P=0.525	P=0.288
POLY 1.5	P=0.179	P=0.627N	P=0.516	P=0.277
POLY 6	P=0.184	P=0.587N	P=0.532	P=0.301
LOGISTIC REGRESSION	P=0.191	P=0.627N	P=0.538	P=0.307
COCH-ARM / FISHERS	P=0.169	P=0.643N	P=0.500	P=0.262
ORDER RESTRICTED	P=0.269	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.282	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Lung: Alveolus  
Infiltration Cellular Histiocyte**

**LESION RATES**

OVERALL (a)	4/50 (8%)	2/50 (4%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	4/44.46	2/47.86	2/46.58	2/46.88
POLY-3 PERCENT (g)	9%	4.2%	4.3%	4.3%
TERMINAL (d)	4/37 (11%)	0/43 (0%)	2/40 (5%)	2/42 (5%)
FIRST INCIDENCE	729 (T)	677	729 (T)	729 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.262N	P=0.272N	P=0.301N	P=0.280N
POLY 3	P=0.287N	P=0.304N	P=0.316N	P=0.313N
POLY 1.5	P=0.288N	P=0.321N	P=0.324N	P=0.323N
POLY 6	P=0.288N	P=0.283N	P=0.308N	P=0.301N
LOGISTIC REGRESSION	P=0.275N	P=0.320N	P=0.301N	P=0.280N
COCH-ARM / FISHERS	P=0.292N	P=0.339N	P=0.339N	P=0.339N
ORDER RESTRICTED	P=0.255N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.269N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Lung: Bronchiole  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/44.46	1/47.46	2/46.58	0/46.88
POLY-3 PERCENT (g)	0%	2.1%	4.3%	0%
TERMINAL (d)	0/37 (0%)	1/43 (2%)	2/40 (5%)	0/42 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.595N	P=0.530	P=0.256	(e)
POLY 3	P=0.598N	P=0.513	P=0.248	(e)
POLY 1.5	P=0.605N	P=0.506	P=0.244	(e)
POLY 6	P=0.589N	P=0.521	P=0.252	(e)
LOGISTIC REGRESSION	(e)	P=0.530	P=0.256	(e)
COCH-ARM / FISHERS	P=0.616N	P=0.500	P=0.247	(e)
ORDER RESTRICTED	P=0.329N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.346N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

Mesentery: Fat  
Necrosis

**LESION RATES**

OVERALL (a)	3/3 (100%)	3/3 (100%)	2/2 (100%)	4/4 (100%)
POLY-3 RATE (b)	3/3.00	3/3.00	2/2.00	4/4.00
POLY-3 PERCENT (g)	100%	100%	100%	100%
TERMINAL (d)	3/3 (100%)	2/2 (100%)	2/2 (100%)	3/3 (100%)
FIRST INCIDENCE	729 (T)	719	729 (T)	667

**STATISTICAL TESTS**

LIFE TABLE	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Nose  
Inflammation**

**LESION RATES**

OVERALL (a)	2/49 (4%)	16/50 (32%)	25/50 (50%)	50/50 (100%)
POLY-3 RATE (b)	2/43.62	16/47.95	25/47.54	50/50.00
POLY-3 PERCENT (g)	4.6%	33.4%	52.6%	100%
TERMINAL (d)	2/37 (5%)	13/43 (30%)	23/40 (58%)	42/42 (100%)
FIRST INCIDENCE	729 (T)	677	493	499

**STATISTICAL TESTS**

LIFE TABLE	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Nose: Glands, Respiratory Epithelium  
Hyperplasia**

**LESION RATES**

OVERALL (a)	17/49 (35%)	29/50 (58%)	40/50 (80%)	50/50 (100%)
POLY-3 RATE (b)	17/44.80	29/48.14	40/48.53	50/50.00
POLY-3 PERCENT (g)	38%	60.2%	82.4%	100%
TERMINAL (d)	14/37 (38%)	27/43 (63%)	35/40 (88%)	42/42 (100%)
FIRST INCIDENCE	509	583	493	499

**STATISTICAL TESTS**

LIFE TABLE	P<0.001**	P=0.063	P<0.001**	P<0.001**
POLY 3	P<0.001**	P=0.023*	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.018*	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.032*	P<0.001**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P=0.028*	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.017*	P<0.001**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Nose: Olfactory Epithelium  
Atrophy**

**LESION RATES**

OVERALL (a)	0/49 (0%)	3/50 (6%)	21/50 (42%)	33/50 (66%)
POLY-3 RATE (b)	0/43.62	3/47.46	21/47.97	33/48.72
POLY-3 PERCENT (g)	0%	6.3%	43.8%	67.7%
TERMINAL (d)	0/37 (0%)	3/43 (7%)	18/40 (45%)	29/42 (69%)
FIRST INCIDENCE	---	729 (T)	493	505

**STATISTICAL TESTS**

LIFE TABLE	P<0.001**	P=0.149	P<0.001**	P<0.001**
POLY 3	P<0.001**	P=0.135	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.128	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.142	P<0.001**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P=0.149	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.125	P<0.001**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Nose: Olfactory Epithelium  
Metaplasia Respiratory**

**LESION RATES**

OVERALL (a)	5/49 (10%)	0/50 (0%)	7/50 (14%)	16/50 (32%)
POLY-3 RATE (b)	5/43.62	0/47.46	7/46.58	16/48.03
POLY-3 PERCENT (g)	11.5%	0%	15%	33.3%
TERMINAL (d)	5/37 (14%)	0/43 (0%)	7/40 (18%)	13/42 (31%)
FIRST INCIDENCE	729 (T)	---	729 (T)	505

**STATISTICAL TESTS**

LIFE TABLE	P<0.001**	P=0.022N*	P=0.434	P=0.017*
POLY 3	P<0.001**	P=0.024N*	P=0.426	P=0.011*
POLY 1.5	P<0.001**	P=0.027N*	P=0.414	P=0.009**
POLY 6	P<0.001**	P=0.021N*	P=0.437	P=0.014*
LOGISTIC REGRESSION	P<0.001**	(e)	P=0.434	P=0.010**
COCH-ARM / FISHERS	P<0.001**	P=0.027N*	P=0.394	P=0.007**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)

TDMS No. 97008-06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 PROPARGYL ALCOHOL  
 CAS Number: 107-19-7

Date Report Reqsted: 07/11/2006  
 Time Report Reqsted: 13:06:48  
 First Dose M/F: 09/17/01 / 09/17/01  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Nose: Respiratory Epithelium  
 Hyperplasia**

**LESION RATES**

OVERALL (a)	1/49 (2%)	49/50 (98%)	49/50 (98%)	50/50 (100%)
POLY-3 RATE (b)	1/43.62	49/49.00	49/49.90	50/50.00
POLY-3 PERCENT (g)	2.3%	100%	98.2%	100%
TERMINAL (d)	1/37 (3%)	43/43 (100%)	40/40 (100%)	42/42 (100%)
FIRST INCIDENCE	729 (T)	572	493	499

**STATISTICAL TESTS**

LIFE TABLE	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)

TDMS No. 97008-06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 PROPARGYL ALCOHOL  
 CAS Number: 107-19-7

Date Report Requested: 07/11/2006  
 Time Report Requested: 13:06:48  
 First Dose M/F: 09/17/01 / 09/17/01  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Nose: Respiratory Epithelium  
 Metaplasia**

**LESION RATES**

OVERALL (a)	2/49 (4%)	11/50 (22%)	36/50 (72%)	50/50 (100%)
POLY-3 RATE (b)	2/43.62	11/47.86	36/48.70	50/50.00
POLY-3 PERCENT (g)	4.6%	23%	73.9%	100%
TERMINAL (d)	2/37 (5%)	9/43 (21%)	30/40 (75%)	42/42 (100%)
FIRST INCIDENCE	729 (T)	677	493	499

**STATISTICAL TESTS**

LIFE TABLE	P<0.001**	P=0.020*	P<0.001**	P<0.001**
POLY 3	P<0.001**	P=0.012*	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.010**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.015*	P<0.001**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P=0.014*	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.008**	P<0.001**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Nose: Respiratory Epithelium  
Necrosis**

**LESION RATES**

OVERALL (a)	0/49 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/43.62	0/47.46	2/47.62	0/46.88
POLY-3 PERCENT (g)	0%	0%	4.2%	0%
TERMINAL (d)	0/37 (0%)	0/43 (0%)	0/40 (0%)	0/42 (0%)
FIRST INCIDENCE	---	---	493	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.604	(e)	P=0.254	(e)
POLY 3	P=0.614	(e)	P=0.257	(e)
POLY 1.5	P=0.609	(e)	P=0.251	(e)
POLY 6	P=0.621	(e)	P=0.263	(e)
LOGISTIC REGRESSION	P=0.534	(e)	P=0.077	(e)
COCH-ARM / FISHERS	P=0.598	(e)	P=0.253	(e)
ORDER RESTRICTED	P=0.265	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.280	(e)	(e)	(e)

TDMS No. 97008-06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

PROPARGYL ALCOHOL

CAS Number: 107-19-7

Date Report Reqsted: 07/11/2006

Time Report Reqsted: 13:06:48

First Dose M/F: 09/17/01 / 09/17/01

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

Nose: Turbinate Atrophy

LESION RATES

OVERALL (a)	0/49 (0%)	50/50 (100%)	49/50 (98%)	50/50 (100%)
POLY-3 RATE (b)	0/43.62	50/50.00	49/50.00	50/50.00
POLY-3 PERCENT (g)	0%	100%	98%	100%
TERMINAL (d)	0/37 (0%)	43/43 (100%)	39/40 (98%)	42/42 (100%)
FIRST INCIDENCE	---	43	493	499

STATISTICAL TESTS

LIFE TABLE	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Pancreas  
Atrophy**

**LESION RATES**

OVERALL (a)	1/49 (2%)	0/50 (0%)	2/49 (4%)	2/50 (4%)
POLY-3 RATE (b)	1/43.62	0/47.46	2/45.93	2/47.20
POLY-3 PERCENT (g)	2.3%	0%	4.4%	4.2%
TERMINAL (d)	1/37 (3%)	0/43 (0%)	2/40 (5%)	1/42 (2%)
FIRST INCIDENCE	729 (T)	---	729 (T)	641

**STATISTICAL TESTS**

LIFE TABLE	P=0.270	P=0.470N	P=0.527	P=0.545
POLY 3	P=0.259	P=0.483N	P=0.518	P=0.527
POLY 1.5	P=0.257	P=0.490N	P=0.511	P=0.519
POLY 6	P=0.262	P=0.476N	P=0.525	P=0.538
LOGISTIC REGRESSION	P=0.253	(e)	P=0.527	P=0.504
COCH-ARM / FISHERS	P=0.249	P=0.495N	P=0.500	P=0.508
ORDER RESTRICTED	P=0.281	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.300	(e)	(e)	(e)

TDMS No. 97008-06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

PROPARGYL ALCOHOL

CAS Number: 107-19-7

Date Report Reqsted: 07/11/2006

Time Report Reqsted: 13:06:48

First Dose M/F: 09/17/01 / 09/17/01

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

Pituitary Gland: Pars Distalis  
Angiectasis

LESION RATES

OVERALL (a)	0/47 (0%)	0/50 (0%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/41.62	0/47.46	0/46.58	0/45.88
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/43 (0%)	0/40 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

LIFE TABLE	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Pituitary Gland: Pars Distalis  
Hyperplasia**

**LESION RATES**

OVERALL (a)	1/47 (2%)	2/50 (4%)	2/50 (4%)	2/49 (4%)
POLY-3 RATE (b)	1/41.94	2/47.46	2/46.70	2/45.88
POLY-3 PERCENT (g)	2.4%	4.2%	4.3%	4.4%
TERMINAL (d)	0/35 (0%)	2/43 (5%)	1/40 (3%)	2/41 (5%)
FIRST INCIDENCE	639	729 (T)	698	729 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.459	P=0.558	P=0.530	P=0.547
POLY 3	P=0.451	P=0.543	P=0.537	P=0.531
POLY 1.5	P=0.445	P=0.532	P=0.532	P=0.525
POLY 6	P=0.457	P=0.555	P=0.542	P=0.539
LOGISTIC REGRESSION	P=0.441	P=0.521	P=0.502	P=0.511
COCH-ARM / FISHERS	P=0.433	P=0.523	P=0.523	P=0.516
ORDER RESTRICTED	P=0.503	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.514	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Preputial Gland  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/44.46	0/47.46	1/46.58	2/47.50
POLY-3 PERCENT (g)	0%	0%	2.2%	4.2%
TERMINAL (d)	0/37 (0%)	0/43 (0%)	1/40 (3%)	1/42 (2%)
FIRST INCIDENCE	---	---	729 (T)	530

**STATISTICAL TESTS**

LIFE TABLE	P=0.076	(e)	P=0.516	P=0.256
POLY 3	P=0.075	(e)	P=0.509	P=0.252
POLY 1.5	P=0.073	(e)	P=0.506	P=0.246
POLY 6	P=0.076	(e)	P=0.513	P=0.260
LOGISTIC REGRESSION	P=0.059	(e)	P=0.516	P=0.175
COCH-ARM / FISHERS	P=0.070	(e)	P=0.500	P=0.247
ORDER RESTRICTED	P=0.084	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.097	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Prostate  
Inflammation**

**LESION RATES**

OVERALL (a)	0/50 (0%)	3/50 (6%)	1/50 (2%)	0/49 (0%)
POLY-3 RATE (b)	0/44.46	3/47.97	1/46.93	0/45.88
POLY-3 PERCENT (g)	0%	6.3%	2.1%	0%
TERMINAL (d)	0/37 (0%)	2/43 (5%)	0/40 (0%)	0/41 (0%)
FIRST INCIDENCE	---	572	630	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.353N	P=0.145	P=0.522	(e)
POLY 3	P=0.344N	P=0.133	P=0.511	(e)
POLY 1.5	P=0.355N	P=0.126	P=0.507	(e)
POLY 6	P=0.330N	P=0.142	P=0.515	(e)
LOGISTIC REGRESSION	P=0.397N	P=0.119	P=0.429	(e)
COCH-ARM / FISHERS	P=0.372N	P=0.121	P=0.500	(e)
ORDER RESTRICTED	P=0.232N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.242N	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Seminal Vesicle  
Inflammation**

**LESION RATES**

OVERALL (a)	0/48 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.40	2/47.97	1/46.93	0/46.88
POLY-3 PERCENT (g)	0%	4.2%	2.1%	0%
TERMINAL (d)	0/37 (0%)	1/43 (2%)	0/40 (0%)	0/42 (0%)
FIRST INCIDENCE	---	572	630	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.447N	P=0.263	P=0.522	(e)
POLY 3	P=0.436N	P=0.260	P=0.516	(e)
POLY 1.5	P=0.444N	P=0.253	P=0.513	(e)
POLY 6	P=0.427N	P=0.270	P=0.519	(e)
LOGISTIC REGRESSION	P=0.483N	P=0.255	P=0.456	(e)
COCH-ARM / FISHERS	P=0.452N	P=0.258	P=0.510	(e)
ORDER RESTRICTED	P=0.330N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.345N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Skin  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	8/50 (16%)	3/50 (6%)	3/50 (6%)	5/50 (10%)
POLY-3 RATE (b)	8/44.95	3/47.66	3/47.46	5/47.98
POLY-3 PERCENT (g)	17.8%	6.3%	6.3%	10.4%
TERMINAL (d)	7/37 (19%)	2/43 (5%)	1/40 (3%)	2/42 (5%)
FIRST INCIDENCE	582	677	565	505

**STATISTICAL TESTS**

LIFE TABLE	P=0.265N	P=0.066N	P=0.084N	P=0.218N
POLY 3	P=0.284N	P=0.081N	P=0.082N	P=0.235N
POLY 1.5	P=0.287N	P=0.091N	P=0.089N	P=0.252N
POLY 6	P=0.280N	P=0.071N	P=0.076N	P=0.215N
LOGISTIC REGRESSION	P=0.324N	P=0.090N	P=0.111N	P=0.300N
COCH-ARM / FISHERS	P=0.298N	P=0.100N	P=0.100N	P=0.277N
ORDER RESTRICTED	P=0.080N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.094N	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Spleen  
Hematopoietic Cell Proliferation**

**LESION RATES**

OVERALL (a)	0/49 (0%)	4/50 (8%)	2/49 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/43.62	4/47.76	2/46.15	0/46.88
POLY-3 PERCENT (g)	0%	8.4%	4.3%	0%
TERMINAL (d)	0/37 (0%)	2/43 (5%)	0/40 (0%)	0/42 (0%)
FIRST INCIDENCE	---	677	698	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.315N	P=0.089	P=0.259	(e)
POLY 3	P=0.300N	P=0.073	P=0.250	(e)
POLY 1.5	P=0.313N	P=0.068	P=0.245	(e)
POLY 6	P=0.285N	P=0.079	P=0.256	(e)
LOGISTIC REGRESSION	P=0.331N	P=0.067	P=0.234	(e)
COCH-ARM / FISHERS	P=0.333N	P=0.061	P=0.247	(e)
ORDER RESTRICTED	P=0.188N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.205N	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Stomach, Forestomach  
Hyperplasia**

**LESION RATES**

OVERALL (a)	3/50 (6%)	1/50 (2%)	2/49 (4%)	6/50 (12%)
POLY-3 RATE (b)	3/45.64	1/47.46	2/46.46	6/47.87
POLY-3 PERCENT (g)	6.6%	2.1%	4.3%	12.5%
TERMINAL (d)	1/37 (3%)	1/43 (2%)	1/40 (3%)	4/42 (10%)
FIRST INCIDENCE	493	729 (T)	565	505

**STATISTICAL TESTS**

LIFE TABLE	P=0.096	P=0.278N	P=0.475N	P=0.296
POLY 3	P=0.083	P=0.292N	P=0.492N	P=0.266
POLY 1.5	P=0.082	P=0.300N	P=0.499N	P=0.257
POLY 6	P=0.084	P=0.282N	P=0.485N	P=0.279
LOGISTIC REGRESSION	P=0.056	P=0.288N	P=0.687	P=0.152
COCH-ARM / FISHERS	P=0.079	P=0.309N	P=0.510N	P=0.243
ORDER RESTRICTED	P=0.077	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.089	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Stomach, Forestomach  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	2/50 (4%)	0/50 (0%)	2/49 (4%)	4/50 (8%)
POLY-3 RATE (b)	2/45.15	0/47.46	2/46.46	4/47.75
POLY-3 PERCENT (g)	4.4%	0%	4.3%	8.4%
TERMINAL (d)	1/37 (3%)	0/43 (0%)	1/40 (3%)	2/42 (5%)
FIRST INCIDENCE	493	---	565	505

**STATISTICAL TESTS**

LIFE TABLE	P=0.125	P=0.223N	P=0.671N	P=0.380
POLY 3	P=0.116	P=0.226N	P=0.683N	P=0.364
POLY 1.5	P=0.115	P=0.233N	P=0.690N	P=0.353
POLY 6	P=0.117	P=0.219N	P=0.676N	P=0.378
LOGISTIC REGRESSION	P=0.079	P=0.211N	P=0.556	P=0.237
COCH-ARM / FISHERS	P=0.111	P=0.247N	P=0.684	P=0.339
ORDER RESTRICTED	P=0.106	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.120	(e)	(e)	(e)



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Stomach, Forestomach  
Ulcer**

**LESION RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.46	1/47.97	0/45.93	0/46.88
POLY-3 PERCENT (g)	0%	2.1%	0%	0%
TERMINAL (d)	0/37 (0%)	0/43 (0%)	0/40 (0%)	0/42 (0%)
FIRST INCIDENCE	---	572	---	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.567N	P=0.513	(e)	(e)
POLY 3	P=0.554N	P=0.515	(e)	(e)
POLY 1.5	P=0.560N	P=0.507	(e)	(e)
POLY 6	P=0.546N	P=0.524	(e)	(e)
LOGISTIC REGRESSION	P=0.619N	P=0.538	(e)	(e)
COCH-ARM / FISHERS	P=0.567N	P=0.500	(e)	(e)
ORDER RESTRICTED	P=0.385N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.399N	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Stomach, Glandular  
Mineralization**

**LESION RATES**

OVERALL (a)	0/49 (0%)	0/50 (0%)	2/49 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/43.62	0/47.46	2/46.53	0/46.88
POLY-3 PERCENT (g)	0%	0%	4.3%	0%
TERMINAL (d)	0/37 (0%)	0/43 (0%)	0/40 (0%)	0/42 (0%)
FIRST INCIDENCE	---	---	640	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.612	(e)	P=0.256	(e)
POLY 3	P=0.614	(e)	P=0.252	(e)
POLY 1.5	P=0.609	(e)	P=0.246	(e)
POLY 6	P=0.620	(e)	P=0.259	(e)
LOGISTIC REGRESSION	P=0.571	(e)	P=0.171	(e)
COCH-ARM / FISHERS	P=0.598	(e)	P=0.247	(e)
ORDER RESTRICTED	P=0.260	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.276	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

**Thyroid Gland: Follicular Cell  
Hyperplasia**

**LESION RATES**

OVERALL (a)	17/49 (35%)	22/50 (44%)	14/50 (28%)	8/50 (16%)
POLY-3 RATE (b)	17/44.60	22/48.19	14/47.36	8/47.24
POLY-3 PERCENT (g)	38.1%	45.7%	29.6%	16.9%
TERMINAL (d)	15/37 (41%)	19/43 (44%)	12/40 (30%)	6/42 (14%)
FIRST INCIDENCE	509	583	493	667

**STATISTICAL TESTS**

LIFE TABLE	P=0.004N**	P=0.406	P=0.252N	P=0.016N*
POLY 3	P=0.003N**	P=0.300	P=0.258N	P=0.018N*
POLY 1.5	P=0.004N**	P=0.259	P=0.276N	P=0.021N*
POLY 6	P=0.003N**	P=0.352	P=0.244N	P=0.015N*
LOGISTIC REGRESSION	P=0.004N**	P=0.291	P=0.269N	P=0.020N*
COCH-ARM / FISHERS	P=0.006N**	P=0.229	P=0.308N	P=0.028N*
ORDER RESTRICTED	P=0.006N**	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.005N**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Urinary Bladder  
Inflammation**

**LESION RATES**

OVERALL (a)	1/49 (2%)	2/50 (4%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.82	2/47.97	0/45.93	0/46.88
POLY-3 PERCENT (g)	2.3%	4.2%	0%	0%
TERMINAL (d)	0/37 (0%)	1/43 (2%)	0/40 (0%)	0/42 (0%)
FIRST INCIDENCE	677	572	---	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.180N	P=0.546	P=0.485N	P=0.476N
POLY 3	P=0.178N	P=0.532	P=0.491N	P=0.487N
POLY 1.5	P=0.181N	P=0.519	P=0.494N	P=0.490N
POLY 6	P=0.174N	P=0.545	P=0.487N	P=0.482N
LOGISTIC REGRESSION	P=0.201N	P=0.510	P=0.524N	P=0.515N
COCH-ARM / FISHERS	P=0.186N	P=0.508	P=0.500N	P=0.495N
ORDER RESTRICTED	P=0.172N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.190N	(e)	(e)	(e)

---

TDMS No. 97008-06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 PROPARGYL ALCOHOL  
 CAS Number: 107-19-7

Date Report Reqsted: 07/11/2006  
 Time Report Reqsted: 13:06:48  
 First Dose M/F: 09/17/01 / 09/17/01  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Adrenal Cortex  
 Hyperplasia**

**LESION RATES**

OVERALL (a)	6/49 (12%)	2/50 (4%)	2/50 (4%)	5/50 (10%)
POLY-3 RATE (b)	6/44.53	2/46.12	2/43.15	5/43.71
POLY-3 PERCENT (g)	13.5%	4.3%	4.6%	11.4%
TERMINAL (d)	6/39 (15%)	2/39 (5%)	2/32 (6%)	5/38 (13%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	731 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.561	P=0.133N	P=0.204N	P=0.518N
POLY 3	P=0.569N	P=0.122N	P=0.143N	P=0.513N
POLY 1.5	P=0.566N	P=0.122N	P=0.134N	P=0.513N
POLY 6	P=0.572N	P=0.124N	P=0.156N	P=0.515N
LOGISTIC REGRESSION	P=0.561	P=0.133N	P=0.204N	P=0.518N
COCH-ARM / FISHERS	P=0.545N	P=0.128N	P=0.128N	P=0.486N
ORDER RESTRICTED	P=0.202N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.212N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Adrenal Cortex  
Hypertrophy**

**LESION RATES**

OVERALL (a)	1/49 (2%)	2/50 (4%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	1/44.53	2/46.12	2/43.27	3/43.71
POLY-3 PERCENT (g)	2.3%	4.3%	4.6%	6.9%
TERMINAL (d)	1/39 (3%)	2/39 (5%)	1/32 (3%)	3/38 (8%)
FIRST INCIDENCE	731 (T)	731 (T)	700	731 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.219	P=0.500	P=0.434	P=0.296
POLY 3	P=0.220	P=0.512	P=0.490	P=0.299
POLY 1.5	P=0.222	P=0.512	P=0.499	P=0.299
POLY 6	P=0.219	P=0.509	P=0.477	P=0.298
LOGISTIC REGRESSION	P=0.218	P=0.500	P=0.476	P=0.296
COCH-ARM / FISHERS	P=0.237	P=0.508	P=0.508	P=0.316
ORDER RESTRICTED	P=0.238	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.246	(e)	(e)	(e)

TDMS No. 97008-06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 PROPARGYL ALCOHOL  
 CAS Number: 107-19-7

Date Report Reqsted: 07/11/2006  
 Time Report Reqsted: 13:06:48  
 First Dose M/F: 09/17/01 / 09/17/01  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Adrenal Medulla  
 Hyperplasia**

**LESION RATES**

OVERALL (a)	2/48 (4%)	2/46 (4%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	2/43.53	2/42.52	2/43.15	2/43.71
POLY-3 PERCENT (g)	4.6%	4.7%	4.6%	4.6%
TERMINAL (d)	2/38 (5%)	2/36 (6%)	2/32 (6%)	2/38 (5%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	731 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.594	P=0.676	P=0.632	P=0.695
POLY 3	P=0.589N	P=0.686	P=0.691	P=0.692N
POLY 1.5	P=0.588N	P=0.685	P=0.688N	P=0.693N
POLY 6	P=0.591N	P=0.683	P=0.677	P=0.693N
LOGISTIC REGRESSION	P=0.594	P=0.676	P=0.632	P=0.695
COCH-ARM / FISHERS	P=0.571N	P=0.675	P=0.676N	P=0.676N
ORDER RESTRICTED	P=0.740N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.740N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Eye  
Cataract**

**LESION RATES**

OVERALL (a)	1/49 (2%)	1/48 (2%)	0/49 (0%)	6/48 (13%)
POLY-3 RATE (b)	1/44.61	1/44.65	0/42.40	6/42.97
POLY-3 PERCENT (g)	2.2%	2.2%	0%	14%
TERMINAL (d)	0/39 (0%)	1/39 (3%)	0/32 (0%)	5/37 (14%)
FIRST INCIDENCE	711	731 (T)	---	658

**STATISTICAL TESTS**

LIFE TABLE	P=0.007**	P=0.758	P=0.532N	P=0.054
POLY 3	P=0.005**	P=0.760N	P=0.510N	P=0.050*
POLY 1.5	P=0.005**	P=0.760	P=0.505N	P=0.050*
POLY 6	P=0.005**	P=0.760	P=0.518N	P=0.049*
LOGISTIC REGRESSION	P=0.006**	P=0.763N	P=0.508N	P=0.051
COCH-ARM / FISHERS	P=0.007**	P=0.747	P=0.500N	P=0.053
ORDER RESTRICTED	P=0.002**	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.004**	(e)	(e)	(e)



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

---

Eye: Cornea  
Fibrosis

**LESION RATES**

OVERALL (a)	0/49 (0%)	0/48 (0%)	0/49 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/44.53	0/44.65	0/42.40	0/42.70
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

LIFE TABLE	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

Eye: Cornea  
Inflammation Chronic

**LESION RATES**

OVERALL (a)	0/49 (0%)	1/48 (2%)	2/49 (4%)	10/48 (21%)
POLY-3 RATE (b)	0/44.53	1/44.65	2/42.40	10/42.97
POLY-3 PERCENT (g)	0%	2.2%	4.7%	23.3%
TERMINAL (d)	0/39 (0%)	1/39 (3%)	2/32 (6%)	9/37 (24%)
FIRST INCIDENCE	---	731 (T)	731 (T)	658

**STATISTICAL TESTS**

LIFE TABLE	P<0.001**	P=0.500	P=0.196	P<0.001**
POLY 3	P<0.001**	P=0.501	P=0.226	P<0.001**
POLY 1.5	P<0.001**	P=0.500	P=0.232	P<0.001**
POLY 6	P<0.001**	P=0.500	P=0.218	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P=0.500	P=0.196	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.495	P=0.247	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

---

Eye: Cornea, Epithelium  
Hyperplasia

**LESION RATES**

OVERALL (a)	0/49 (0%)	0/48 (0%)	0/49 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/44.53	0/44.65	0/42.40	0/42.70
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

LIFE TABLE	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Harderian Gland  
Hyperplasia**

**LESION RATES**

OVERALL (a)	2/50 (4%)	1/49 (2%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	2/45.42	1/45.52	2/43.88	2/43.71
POLY-3 PERCENT (g)	4.4%	2.2%	4.6%	4.6%
TERMINAL (d)	2/39 (5%)	1/39 (3%)	1/32 (3%)	2/38 (5%)
FIRST INCIDENCE	731 (T)	731 (T)	467	731 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.507	P=0.500N	P=0.644	P=0.686
POLY 3	P=0.506	P=0.499N	P=0.682	P=0.680
POLY 1.5	P=0.507	P=0.501N	P=0.688	P=0.680
POLY 6	P=0.506	P=0.501N	P=0.670	P=0.680
LOGISTIC REGRESSION	P=0.528	P=0.500N	P=0.685N	P=0.686
COCH-ARM / FISHERS	P=0.529	P=0.508N	P=0.691N	P=0.691N
ORDER RESTRICTED	P=0.591	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.597	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Heart  
Cardiomyopathy**

**LESION RATES**

OVERALL (a)	2/50 (4%)	5/50 (10%)	7/50 (14%)	3/50 (6%)
POLY-3 RATE (b)	2/45.42	5/46.12	7/44.46	3/43.96
POLY-3 PERCENT (g)	4.4%	10.8%	15.7%	6.8%
TERMINAL (d)	2/39 (5%)	5/39 (13%)	3/32 (9%)	2/38 (5%)
FIRST INCIDENCE	731 (T)	731 (T)	565	663

**STATISTICAL TESTS**

LIFE TABLE	P=0.449	P=0.216	P=0.055	P=0.486
POLY 3	P=0.449	P=0.222	P=0.073	P=0.485
POLY 1.5	P=0.447	P=0.223	P=0.077	P=0.484
POLY 6	P=0.454	P=0.218	P=0.069	P=0.487
LOGISTIC REGRESSION	P=0.463	P=0.216	P=0.083	P=0.483
COCH-ARM / FISHERS	P=0.483	P=0.218	P=0.080	P=0.500
ORDER RESTRICTED	P=0.208	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.220	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

Heart: Artery  
Inflammation Chronic

**LESION RATES**

OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/46.18	2/46.82	0/43.15	1/44.34
POLY-3 PERCENT (g)	2.2%	4.3%	0%	2.3%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	453	605	---	523

**STATISTICAL TESTS**

LIFE TABLE	P=0.512N	P=0.515	P=0.496N	P=0.753
POLY 3	P=0.513N	P=0.505	P=0.514N	P=0.751
POLY 1.5	P=0.510N	P=0.504	P=0.507N	P=0.751
POLY 6	P=0.517N	P=0.504	P=0.522N	P=0.752
LOGISTIC REGRESSION	P=0.302N	P=0.302	P=0.644N	P=0.658N
COCH-ARM / FISHERS	P=0.500N	P=0.500	P=0.500N	P=0.753N
ORDER RESTRICTED	P=0.398N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.410N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Islets, Pancreatic  
Hyperplasia**

**LESION RATES**

OVERALL (a)	1/50 (2%)	1/48 (2%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	1/45.42	1/44.88	0/43.15	0/43.70
POLY-3 PERCENT (g)	2.2%	2.2%	0%	0%
TERMINAL (d)	1/39 (3%)	1/39 (3%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	731 (T)	731 (T)	---	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.248N	P=0.762	P=0.539N	P=0.505N
POLY 3	P=0.242N	P=0.758	P=0.510N	P=0.508N
POLY 1.5	P=0.240N	P=0.756	P=0.505N	P=0.508N
POLY 6	P=0.244N	P=0.758	P=0.518N	P=0.508N
LOGISTIC REGRESSION	P=0.248N	P=0.762	(e)	(e)
COCH-ARM / FISHERS	P=0.237N	P=0.742	P=0.500N	P=0.505N
ORDER RESTRICTED	P=0.256N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.267N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Kidney  
Amyloid Deposition**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/45.42	0/46.12	0/43.15	2/45.70
POLY-3 PERCENT (g)	0%	0%	0%	4.4%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	---	---	---	81

**STATISTICAL TESTS**

LIFE TABLE	P=0.046*	(e)	(e)	P=0.238
POLY 3	P=0.045*	(e)	(e)	P=0.239
POLY 1.5	P=0.045*	(e)	(e)	P=0.238
POLY 6	P=0.045*	(e)	(e)	P=0.239
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
ORDER RESTRICTED	P=0.030*	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.033*	(e)	(e)	(e)



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Kidney  
Cyst**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.42	0/46.12	0/43.15	0/43.71
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

LIFE TABLE	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Kidney  
Inflammation**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/45.42	0/46.12	1/43.40	0/43.71
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	---	---	664	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.683	(e)	P=0.481	(e)
POLY 3	P=0.679	(e)	P=0.491	(e)
POLY 1.5	P=0.677	(e)	P=0.495	(e)
POLY 6	P=0.682	(e)	P=0.484	(e)
LOGISTIC REGRESSION	P=0.711	(e)	P=0.505	(e)
COCH-ARM / FISHERS	P=0.694	(e)	P=0.500	(e)
ORDER RESTRICTED	P=0.373	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.384	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Kidney  
Metaplasia Osseous**

**LESION RATES**

OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/45.92	1/46.12	0/43.15	1/43.71
POLY-3 PERCENT (g)	2.2%	2.2%	0%	2.3%
TERMINAL (d)	0/39 (0%)	1/39 (3%)	0/32 (0%)	1/38 (3%)
FIRST INCIDENCE	579	731 (T)	---	731 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.626N	P=0.760	P=0.513N	P=0.753
POLY 3	P=0.624N	P=0.760N	P=0.512N	P=0.750
POLY 1.5	P=0.621N	P=0.759N	P=0.506N	P=0.750
POLY 6	P=0.628N	P=0.758	P=0.521N	P=0.748
LOGISTIC REGRESSION	P=0.607N	P=0.735	P=0.514N	P=0.752N
COCH-ARM / FISHERS	P=0.616N	P=0.753N	P=0.500N	P=0.753N
ORDER RESTRICTED	P=0.554N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.563N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Kidney  
Nephropathy**

**LESION RATES**

OVERALL (a)	20/50 (40%)	19/50 (38%)	19/50 (38%)	24/50 (48%)
POLY-3 RATE (b)	20/47.17	19/46.95	19/47.11	24/46.26
POLY-3 PERCENT (g)	42.4%	40.5%	40.3%	51.9%
TERMINAL (d)	16/39 (41%)	16/39 (41%)	9/32 (28%)	18/38 (47%)
FIRST INCIDENCE	369	605	467	219

**STATISTICAL TESTS**

LIFE TABLE	P=0.174	P=0.501N	P=0.427	P=0.251
POLY 3	P=0.177	P=0.508N	P=0.502N	P=0.238
POLY 1.5	P=0.171	P=0.499N	P=0.498N	P=0.232
POLY 6	P=0.185	P=0.528N	P=0.513N	P=0.245
LOGISTIC REGRESSION	P=0.198	P=0.485N	P=0.472N	P=0.252
COCH-ARM / FISHERS	P=0.204	P=0.500N	P=0.500N	P=0.273
ORDER RESTRICTED	P=0.230	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.238	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Kidney: Pelvis  
Dilatation**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.42	0/46.12	0/43.15	0/43.71
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

LIFE TABLE	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

Liver  
Basophilic Focus

**LESION RATES**

OVERALL (a)	1/50 (2%)	3/50 (6%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	1/45.42	3/46.38	2/43.15	3/43.71
POLY-3 PERCENT (g)	2.2%	6.5%	4.6%	6.9%
TERMINAL (d)	1/39 (3%)	2/39 (5%)	2/32 (6%)	3/38 (8%)
FIRST INCIDENCE	731 (T)	660	731 (T)	731 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.286	P=0.307	P=0.431	P=0.296
POLY 3	P=0.281	P=0.313	P=0.482	P=0.292
POLY 1.5	P=0.282	P=0.312	P=0.491	P=0.292
POLY 6	P=0.279	P=0.311	P=0.468	P=0.291
LOGISTIC REGRESSION	P=0.281	P=0.309	P=0.431	P=0.296
COCH-ARM / FISHERS	P=0.302	P=0.309	P=0.500	P=0.309
ORDER RESTRICTED	P=0.252	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.264	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

Liver  
Clear Cell Focus

**LESION RATES**

OVERALL (a)	2/50 (4%)	3/50 (6%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	2/45.42	3/46.25	3/43.30	2/43.71
POLY-3 PERCENT (g)	4.4%	6.5%	6.9%	4.6%
TERMINAL (d)	2/39 (5%)	2/39 (5%)	2/32 (6%)	2/38 (5%)
FIRST INCIDENCE	731 (T)	698	691	731 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.571N	P=0.496	P=0.415	P=0.686
POLY 3	P=0.568N	P=0.508	P=0.478	P=0.680
POLY 1.5	P=0.567N	P=0.507	P=0.489	P=0.680
POLY 6	P=0.570N	P=0.505	P=0.462	P=0.680
LOGISTIC REGRESSION	P=0.570N	P=0.501	P=0.454	P=0.686
COCH-ARM / FISHERS	P=0.544N	P=0.500	P=0.500	P=0.691N
ORDER RESTRICTED	P=0.582	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.588	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

Liver  
Eosinophilic Focus

**LESION RATES**

OVERALL (a)	6/50 (12%)	7/50 (14%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	6/45.73	7/46.12	3/43.15	0/43.71
POLY-3 PERCENT (g)	13.1%	15.2%	7%	0%
TERMINAL (d)	5/39 (13%)	7/39 (18%)	3/32 (9%)	0/38 (0%)
FIRST INCIDENCE	647	731 (T)	731 (T)	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.009N**	P=0.500	P=0.342N	P=0.020N*
POLY 3	P=0.008N**	P=0.507	P=0.271N	P=0.018N*
POLY 1.5	P=0.008N**	P=0.509	P=0.257N	P=0.018N*
POLY 6	P=0.008N**	P=0.496	P=0.294N	P=0.018N*
LOGISTIC REGRESSION	P=0.009N**	P=0.502	P=0.287N	P=0.020N*
COCH-ARM / FISHERS	P=0.007N**	P=0.500	P=0.243N	P=0.013N*
ORDER RESTRICTED	P=0.011N*	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.011N*	(e)	(e)	(e)



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Liver  
Hematopoietic Cell Proliferation**

**LESION RATES**

OVERALL (a)	2/50 (4%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	2/47.14	0/46.12	2/44.67	1/44.68
POLY-3 PERCENT (g)	4.2%	0%	4.5%	2.2%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	369	---	436	219

**STATISTICAL TESTS**

LIFE TABLE	P=0.548N	P=0.238N	P=0.682N	P=0.519N
POLY 3	P=0.543N	P=0.242N	P=0.674	P=0.519N
POLY 1.5	P=0.542N	P=0.240N	P=0.683	P=0.516N
POLY 6	P=0.542N	P=0.246N	P=0.662	P=0.521N
LOGISTIC REGRESSION	P=0.047N*	(e)	P=0.349	P=0.113N
COCH-ARM / FISHERS	P=0.531N	P=0.247N	P=0.691N	P=0.500N
ORDER RESTRICTED	P=0.437N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.450N	(e)	(e)	(e)

TDMS No. 97008-06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 PROPARGYL ALCOHOL  
 CAS Number: 107-19-7

Date Report Requested: 07/11/2006  
 Time Report Requested: 13:06:48  
 First Dose M/F: 09/17/01 / 09/17/01  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

Liver  
 Necrosis

**LESION RATES**

OVERALL (a)	2/50 (4%)	0/50 (0%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	2/46.27	0/46.12	2/44.27	2/44.56
POLY-3 PERCENT (g)	4.3%	0%	4.5%	4.5%
TERMINAL (d)	1/39 (3%)	0/39 (0%)	0/32 (0%)	1/38 (3%)
FIRST INCIDENCE	389	---	467	388

**STATISTICAL TESTS**

LIFE TABLE	P=0.431	P=0.238N	P=0.676	P=0.678
POLY 3	P=0.429	P=0.238N	P=0.678	P=0.680
POLY 1.5	P=0.428	P=0.237N	P=0.685	P=0.680
POLY 6	P=0.432	P=0.241N	P=0.667	P=0.680
LOGISTIC REGRESSION	P=0.538N	P=0.365N	P=0.686	P=0.590N
COCH-ARM / FISHERS	P=0.444	P=0.247N	P=0.691N	P=0.691N
ORDER RESTRICTED	P=0.423	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.434	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

Liver  
Tension Lipidosis

**LESION RATES**

OVERALL (a)	2/50 (4%)	1/50 (2%)	5/50 (10%)	2/50 (4%)
POLY-3 RATE (b)	2/45.53	1/46.39	5/43.30	2/43.71
POLY-3 PERCENT (g)	4.4%	2.2%	11.6%	4.6%
TERMINAL (d)	1/39 (3%)	0/39 (0%)	4/32 (13%)	2/38 (5%)
FIRST INCIDENCE	704	659	691	731 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.429	P=0.506N	P=0.150	P=0.678
POLY 3	P=0.423	P=0.493N	P=0.196	P=0.679
POLY 1.5	P=0.424	P=0.494N	P=0.206	P=0.679
POLY 6	P=0.423	P=0.496N	P=0.181	P=0.678
LOGISTIC REGRESSION	P=0.433	P=0.504N	P=0.179	P=0.681
COCH-ARM / FISHERS	P=0.456	P=0.500N	P=0.218	P=0.691N
ORDER RESTRICTED	P=0.258	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.270	(e)	(e)	(e)

TDMS No. 97008-06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 PROPARGYL ALCOHOL  
 CAS Number: 107-19-7

Date Report Reqsted: 07/11/2006  
 Time Report Reqsted: 13:06:48  
 First Dose M/F: 09/17/01 / 09/17/01  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

Lung  
 Inflammation Chronic

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.42	0/46.12	0/43.15	0/43.71
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

LIFE TABLE	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Lung: Alveolar Epithelium  
Hyperplasia**

**LESION RATES**

OVERALL (a)	7/50 (14%)	6/50 (12%)	3/50 (6%)	4/50 (8%)
POLY-3 RATE (b)	7/45.42	6/46.25	3/43.15	4/43.91
POLY-3 PERCENT (g)	15.4%	13%	7%	9.1%
TERMINAL (d)	7/39 (18%)	5/39 (13%)	3/32 (9%)	3/38 (8%)
FIRST INCIDENCE	731 (T)	698	731 (T)	677

**STATISTICAL TESTS**

LIFE TABLE	P=0.198N	P=0.503N	P=0.246N	P=0.279N
POLY 3	P=0.188N	P=0.486N	P=0.178N	P=0.280N
POLY 1.5	P=0.187N	P=0.488N	P=0.168N	P=0.282N
POLY 6	P=0.188N	P=0.491N	P=0.195N	P=0.278N
LOGISTIC REGRESSION	P=0.196N	P=0.509N	P=0.246N	P=0.284N
COCH-ARM / FISHERS	P=0.169N	P=0.500N	P=0.159N	P=0.262N
ORDER RESTRICTED	P=0.212N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.224N	(e)	(e)	(e)

TDMS No. 97008-06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 PROPARGYL ALCOHOL  
 CAS Number: 107-19-7

Date Report Requested: 07/11/2006  
 Time Report Requested: 13:06:48  
 First Dose M/F: 09/17/01 / 09/17/01  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

Lung: Alveolus  
 Infiltration Cellular Histiocyte

**LESION RATES**

OVERALL (a)	1/50 (2%)	1/50 (2%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	1/45.42	1/46.12	2/43.15	2/44.08
POLY-3 PERCENT (g)	2.2%	2.2%	4.6%	4.5%
TERMINAL (d)	1/39 (3%)	1/39 (3%)	2/32 (6%)	1/38 (3%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	626

**STATISTICAL TESTS**

LIFE TABLE	P=0.327	P=0.762	P=0.431	P=0.497
POLY 3	P=0.322	P=0.757N	P=0.482	P=0.490
POLY 1.5	P=0.321	P=0.757N	P=0.491	P=0.488
POLY 6	P=0.325	P=0.759N	P=0.468	P=0.491
LOGISTIC REGRESSION	P=0.321	P=0.762	P=0.431	P=0.495
COCH-ARM / FISHERS	P=0.337	P=0.753N	P=0.500	P=0.500
ORDER RESTRICTED	P=0.420	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.430	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Lung: Bronchiole  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.42	0/46.12	0/43.15	0/43.71
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

LIFE TABLE	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Mesentery: Fat  
Necrosis**

**LESION RATES**

OVERALL (a)	8/9 (89%)	11/13 (85%)	5/7 (71%)	4/5 (80%)
POLY-3 RATE (b)	8/8.24	11/12.45	5/6.66	4/4.63
POLY-3 PERCENT (g)	97.1%	88.4%	75.1%	86.3%
TERMINAL (d)	7/7 (100%)	10/11 (91%)	5/5 (100%)	3/3 (100%)
FIRST INCIDENCE	592	660	731 (T)	219

**STATISTICAL TESTS**

LIFE TABLE	P=0.627	P=0.549N	P=0.523N	P=0.755
POLY 3	P=0.358N	P=0.549N	P=0.293N	P=0.704N
POLY 1.5	P=0.364N	P=0.577N	P=0.328N	P=0.642N
POLY 6	P=0.406N	P=0.546N	P=0.300N	P=0.902N
LOGISTIC REGRESSION	P=0.572N	P=0.357N	P=0.139N	P=0.782N
COCH-ARM / FISHERS	P=0.402N	P=0.642N	P=0.400N	P=0.604N
ORDER RESTRICTED	P=0.323N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.312N	(e)	(e)	(e)



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Nose  
Inflammation**

**LESION RATES**

OVERALL (a)	1/50 (2%)	4/50 (8%)	35/50 (70%)	45/50 (90%)
POLY-3 RATE (b)	1/45.42	4/46.81	35/45.33	45/46.41
POLY-3 PERCENT (g)	2.2%	8.6%	77.2%	97%
TERMINAL (d)	1/39 (3%)	3/39 (8%)	27/32 (84%)	38/38 (100%)
FIRST INCIDENCE	731 (T)	495	565	388

**STATISTICAL TESTS**

LIFE TABLE	P<0.001**	P=0.185	P<0.001**	P<0.001**
POLY 3	P<0.001**	P=0.188	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.186	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.187	P<0.001**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P=0.163	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.181	P<0.001**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)

TDMS No. 97008-06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

PROPARGYL ALCOHOL

CAS Number: 107-19-7

Date Report Reqsted: 07/11/2006

Time Report Reqsted: 13:06:48

First Dose M/F: 09/17/01 / 09/17/01

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

Nose: Glands, Respiratory Epithelium  
Hyperplasia

LESION RATES

OVERALL (a)	7/50 (14%)	24/50 (48%)	44/50 (88%)	49/50 (98%)
POLY-3 RATE (b)	7/45.48	24/47.24	44/48.09	49/49.00
POLY-3 PERCENT (g)	15.4%	50.8%	91.5%	100%
TERMINAL (d)	6/39 (15%)	21/39 (54%)	31/32 (97%)	38/38 (100%)
FIRST INCIDENCE	716	558	509	117

STATISTICAL TESTS

LIFE TABLE	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Nose: Olfactory Epithelium Atrophy**

**LESION RATES**

OVERALL (a)	2/50 (4%)	5/50 (10%)	31/50 (62%)	29/50 (58%)
POLY-3 RATE (b)	2/45.48	5/46.12	31/46.83	29/46.79
POLY-3 PERCENT (g)	4.4%	10.8%	66.2%	62%
TERMINAL (d)	1/39 (3%)	5/39 (13%)	19/32 (59%)	23/38 (61%)
FIRST INCIDENCE	716	731 (T)	509	219

**STATISTICAL TESTS**

LIFE TABLE	P<0.001**	P=0.217	P<0.001**	P<0.001**
POLY 3	P<0.001**	P=0.222	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.222	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.217	P<0.001**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P=0.210	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.218	P<0.001**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM
<b>Nose: Olfactory Epithelium Metaplasia Respiratory</b>				
<b>LESION RATES</b>				
OVERALL (a)	1/50 (2%)	0/50 (0%)	6/50 (12%)	14/50 (28%)
POLY-3 RATE (b)	1/45.42	0/46.12	6/43.40	14/44.40
POLY-3 PERCENT (g)	2.2%	0%	13.8%	31.5%
TERMINAL (d)	1/39 (3%)	0/39 (0%)	5/32 (16%)	12/38 (32%)
FIRST INCIDENCE	731 (T)	---	664	626

**STATISTICAL TESTS**

LIFE TABLE	P<0.001**	P=0.500N	P=0.035*	P<0.001**
POLY 3	P<0.001**	P=0.497N	P=0.048*	P<0.001**
POLY 1.5	P<0.001**	P=0.497N	P=0.052	P<0.001**
POLY 6	P<0.001**	P=0.499N	P=0.043*	P<0.001**
LOGISTIC REGRESSION	P<0.001**	(e)	P=0.044*	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.500N	P=0.056	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)

TDMS No. 97008-06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 PROPARGYL ALCOHOL  
 CAS Number: 107-19-7

Date Report Requested: 07/11/2006  
 Time Report Requested: 13:06:48  
 First Dose M/F: 09/17/01 / 09/17/01  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Nose: Respiratory Epithelium  
 Hyperplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	50/50 (100%)	50/50 (100%)	49/50 (98%)
POLY-3 RATE (b)	0/45.42	50/50.00	50/50.00	49/49.03
POLY-3 PERCENT (g)	0%	100%	100%	100%
TERMINAL (d)	0/39 (0%)	39/39 (100%)	32/32 (100%)	38/38 (100%)
FIRST INCIDENCE	---	495	436	81

**STATISTICAL TESTS**

LIFE TABLE	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)

TDMS No. 97008-06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 PROPARGYL ALCOHOL  
 CAS Number: 107-19-7

Date Report Requested: 07/11/2006  
 Time Report Requested: 13:06:48  
 First Dose M/F: 09/17/01 / 09/17/01  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Nose: Respiratory Epithelium  
 Metaplasia**

**LESION RATES**

OVERALL (a)	0/50 (0%)	3/50 (6%)	34/50 (68%)	49/50 (98%)
POLY-3 RATE (b)	0/45.42	3/47.24	34/47.14	49/49.95
POLY-3 PERCENT (g)	0%	6.4%	72.1%	98.1%
TERMINAL (d)	0/39 (0%)	1/39 (3%)	21/32 (66%)	38/38 (100%)
FIRST INCIDENCE	---	495	467	81

**STATISTICAL TESTS**

LIFE TABLE	P<0.001**	P=0.132	P<0.001**	P<0.001**
POLY 3	P<0.001**	P=0.126	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.124	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.126	P<0.001**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P=0.055	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.121	P<0.001**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

Nose: Respiratory Epithelium  
Necrosis

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.42	0/46.12	0/43.15	0/43.71
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

LIFE TABLE	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Nose: Turbinate Atrophy**

**LESION RATES**

OVERALL (a)	0/50 (0%)	50/50 (100%)	50/50 (100%)	50/50 (100%)
POLY-3 RATE (b)	0/45.42	50/50.00	50/50.00	50/50.00
POLY-3 PERCENT (g)	0%	100%	100%	100%
TERMINAL (d)	0/39 (0%)	39/39 (100%)	32/32 (100%)	38/38 (100%)
FIRST INCIDENCE	---	495	436	81

**STATISTICAL TESTS**

LIFE TABLE	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Ovary  
Cyst**

**LESION RATES**

OVERALL (a)	10/49 (20%)	13/50 (26%)	15/49 (31%)	9/49 (18%)
POLY-3 RATE (b)	10/45.99	13/46.66	15/42.96	9/42.71
POLY-3 PERCENT (g)	21.7%	27.9%	34.9%	21.1%
TERMINAL (d)	8/39 (21%)	12/39 (31%)	13/31 (42%)	9/37 (24%)
FIRST INCIDENCE	453	565	467	731 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.489N	P=0.322	P=0.067	P=0.550N
POLY 3	P=0.512N	P=0.330	P=0.124	P=0.572N
POLY 1.5	P=0.493N	P=0.338	P=0.148	P=0.559N
POLY 6	P=0.535N	P=0.311	P=0.095	P=0.588N
LOGISTIC REGRESSION	P=0.466N	P=0.338	P=0.160	P=0.533N
COCH-ARM / FISHERS	P=0.407N	P=0.337	P=0.177	P=0.500N
ORDER RESTRICTED	P=0.363N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.380N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Ovary  
Thrombosis**

**LESION RATES**

OVERALL (a)	0/49 (0%)	2/50 (4%)	0/49 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/44.73	2/46.29	0/42.15	0/42.71
POLY-3 PERCENT (g)	0%	4.3%	0%	0%
TERMINAL (d)	0/39 (0%)	1/39 (3%)	0/31 (0%)	0/37 (0%)
FIRST INCIDENCE	---	688	---	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.426N	P=0.237	(e)	(e)
POLY 3	P=0.416N	P=0.245	(e)	(e)
POLY 1.5	P=0.413N	P=0.245	(e)	(e)
POLY 6	P=0.422N	P=0.242	(e)	(e)
LOGISTIC REGRESSION	P=0.415N	P=0.243	(e)	(e)
COCH-ARM / FISHERS	P=0.406N	P=0.253	(e)	(e)
ORDER RESTRICTED	P=0.263N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.276N	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Pancreas  
Atrophy**

**LESION RATES**

OVERALL (a)	1/50 (2%)	1/48 (2%)	1/50 (2%)	2/49 (4%)
POLY-3 RATE (b)	1/45.53	1/45.15	1/43.15	2/43.70
POLY-3 PERCENT (g)	2.2%	2.2%	2.3%	4.6%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	1/32 (3%)	2/38 (5%)
FIRST INCIDENCE	704	660	731 (T)	731 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.335	P=0.752	P=0.715	P=0.483
POLY 3	P=0.338	P=0.759	P=0.749	P=0.486
POLY 1.5	P=0.339	P=0.757	P=0.755	P=0.486
POLY 6	P=0.335	P=0.759	P=0.739	P=0.485
LOGISTIC REGRESSION	P=0.340	P=0.741	P=0.748	P=0.486
COCH-ARM / FISHERS	P=0.349	P=0.742	P=0.753N	P=0.492
ORDER RESTRICTED	P=0.396	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.407	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Pituitary Gland: Pars Distalis  
Angiectasis**

**LESION RATES**

OVERALL (a)	5/50 (10%)	2/49 (4%)	0/48 (0%)	3/50 (6%)
POLY-3 RATE (b)	5/46.26	2/45.52	0/41.33	3/43.71
POLY-3 PERCENT (g)	10.8%	4.4%	0%	6.9%
TERMINAL (d)	3/39 (8%)	2/39 (5%)	0/31 (0%)	3/38 (8%)
FIRST INCIDENCE	453	731 (T)	---	731 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.318N	P=0.220N	P=0.052N	P=0.375N
POLY 3	P=0.308N	P=0.223N	P=0.041N*	P=0.388N
POLY 1.5	P=0.304N	P=0.222N	P=0.038N*	P=0.385N
POLY 6	P=0.313N	P=0.227N	P=0.046N*	P=0.392N
LOGISTIC REGRESSION	P=0.301N	P=0.240N	P=0.034N*	P=0.362N
COCH-ARM / FISHERS	P=0.292N	P=0.226N	P=0.031N*	P=0.357N
ORDER RESTRICTED	P=0.099N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.114N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Pituitary Gland: Pars Distalis  
Hyperplasia**

**LESION RATES**

OVERALL (a)	23/50 (46%)	11/49 (22%)	14/48 (29%)	9/50 (18%)
POLY-3 RATE (b)	23/46.00	11/46.08	14/42.59	9/43.71
POLY-3 PERCENT (g)	50%	23.9%	32.9%	20.6%
TERMINAL (d)	21/39 (54%)	8/39 (21%)	9/31 (29%)	9/38 (24%)
FIRST INCIDENCE	579	659	544	731 (T)

**STATISTICAL TESTS**

LIFE TABLE	P=0.012N*	P=0.012N*	P=0.195N	P=0.003N**
POLY 3	P=0.008N**	P=0.007N**	P=0.074N	P=0.003N**
POLY 1.5	P=0.008N**	P=0.008N**	P=0.067N	P=0.003N**
POLY 6	P=0.008N**	P=0.007N**	P=0.087N	P=0.003N**
LOGISTIC REGRESSION	P=0.009N**	P=0.009N**	P=0.095N	P=0.003N**
COCH-ARM / FISHERS	P=0.006N**	P=0.012N*	P=0.065N	P=0.002N**
ORDER RESTRICTED	P<0.001N**	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.002N**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Skin  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/45.42	2/46.65	1/43.81	1/44.34
POLY-3 PERCENT (g)	0%	4.3%	2.3%	2.3%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	---	659	509	523

**STATISTICAL TESTS**

LIFE TABLE	P=0.486	P=0.242	P=0.504	P=0.496
POLY 3	P=0.488	P=0.243	P=0.493	P=0.495
POLY 1.5	P=0.486	P=0.242	P=0.497	P=0.494
POLY 6	P=0.490	P=0.243	P=0.486	P=0.496
LOGISTIC REGRESSION	P=0.629N	P=0.202	P=0.437	P=0.590
COCH-ARM / FISHERS	P=0.500	P=0.247	P=0.500	P=0.500
ORDER RESTRICTED	P=0.273	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.282	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Spleen  
Hematopoietic Cell Proliferation**

**LESION RATES**

OVERALL (a)	3/50 (6%)	4/48 (8%)	3/50 (6%)	4/50 (8%)
POLY-3 RATE (b)	3/45.53	4/45.83	3/44.75	4/44.95
POLY-3 PERCENT (g)	6.6%	8.7%	6.7%	8.9%
TERMINAL (d)	2/39 (5%)	2/39 (5%)	0/32 (0%)	2/38 (5%)
FIRST INCIDENCE	704	495	526	219

**STATISTICAL TESTS**

LIFE TABLE	P=0.437	P=0.499	P=0.608	P=0.480
POLY 3	P=0.454	P=0.504	P=0.654	P=0.493
POLY 1.5	P=0.454	P=0.496	P=0.659	P=0.490
POLY 6	P=0.453	P=0.508	P=0.645	P=0.495
LOGISTIC REGRESSION	P=0.529N	P=0.441	P=0.650N	P=0.548
COCH-ARM / FISHERS	P=0.471	P=0.477	P=0.661N	P=0.500
ORDER RESTRICTED	P=0.536	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.543	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Stomach, Forestomach  
Hyperplasia**

**LESION RATES**

OVERALL (a)	3/50 (6%)	2/50 (4%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	3/46.88	2/46.82	2/44.04	1/44.68
POLY-3 PERCENT (g)	6.4%	4.3%	4.5%	2.2%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	389	605	579	219

**STATISTICAL TESTS**

LIFE TABLE	P=0.252N	P=0.499N	P=0.532N	P=0.330N
POLY 3	P=0.250N	P=0.501N	P=0.528N	P=0.323N
POLY 1.5	P=0.247N	P=0.499N	P=0.516N	P=0.320N
POLY 6	P=0.254N	P=0.505N	P=0.545N	P=0.327N
LOGISTIC REGRESSION	P=0.055N	P=0.695	P=0.508N	P=0.112N
COCH-ARM / FISHERS	P=0.232N	P=0.500N	P=0.500N	P=0.309N
ORDER RESTRICTED	P=0.265N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.278N	(e)	(e)	(e)

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Stomach, Forestomach  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/45.92	0/46.12	2/44.04	0/43.71
POLY-3 PERCENT (g)	2.2%	0%	4.5%	0%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	579	---	579	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.469N	P=0.500N	P=0.479	P=0.509N
POLY 3	P=0.478N	P=0.499N	P=0.485	P=0.510N
POLY 1.5	P=0.477N	P=0.498N	P=0.493	P=0.509N
POLY 6	P=0.477N	P=0.502N	P=0.474	P=0.511N
LOGISTIC REGRESSION	P=0.337N	P=0.614N	P=0.493	P=0.447N
COCH-ARM / FISHERS	P=0.461N	P=0.500N	P=0.500	P=0.500N
ORDER RESTRICTED	P=0.329N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.345N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

**Stomach, Forestomach  
Ulcer**

**LESION RATES**

OVERALL (a)	2/50 (4%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	2/46.38	2/46.82	1/43.54	1/44.56
POLY-3 PERCENT (g)	4.3%	4.3%	2.3%	2.2%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	389	605	620	388

**STATISTICAL TESTS**

LIFE TABLE	P=0.355N	P=0.690N	P=0.527N	P=0.523N
POLY 3	P=0.354N	P=0.690N	P=0.522N	P=0.514N
POLY 1.5	P=0.351N	P=0.690N	P=0.512N	P=0.514N
POLY 6	P=0.357N	P=0.692N	P=0.535N	P=0.515N
LOGISTIC REGRESSION	P=0.143N	P=0.539	P=0.520N	P=0.316N
COCH-ARM / FISHERS	P=0.337N	P=0.691N	P=0.500N	P=0.500N
ORDER RESTRICTED	P=0.461N	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.472N	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

---

**Stomach, Glandular  
Mineralization**

**LESION RATES**

OVERALL (a)	0/50 (0%)	0/48 (0%)	0/48 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/45.42	0/44.88	0/41.60	0/43.70
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/39 (0%)	0/39 (0%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	---	---	---	---

**STATISTICAL TESTS**

LIFE TABLE	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

---

TDMS No. 97008-06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

PROPARGYL ALCOHOL

CAS Number: 107-19-7

Date Report Requested: 07/11/2006

Time Report Requested: 13:06:48

First Dose M/F: 09/17/01 / 09/17/01

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

Thyroid Gland: Follicular Cell  
Hyperplasia

LESION RATES

OVERALL (a)	11/50 (22%)	13/50 (26%)	14/50 (28%)	11/50 (22%)
POLY-3 RATE (b)	11/45.48	13/46.72	14/44.18	11/44.93
POLY-3 PERCENT (g)	24.2%	27.8%	31.7%	24.5%
TERMINAL (d)	10/39 (26%)	11/39 (28%)	10/32 (31%)	8/38 (21%)
FIRST INCIDENCE	716	605	436	388

STATISTICAL TESTS

LIFE TABLE	P=0.519	P=0.409	P=0.167	P=0.568
POLY 3	P=0.542N	P=0.436	P=0.288	P=0.584
POLY 1.5	P=0.539	P=0.430	P=0.308	P=0.573
POLY 6	P=0.534N	P=0.434	P=0.257	P=0.593
LOGISTIC REGRESSION	P=0.526	P=0.413	P=0.257	P=0.562
COCH-ARM / FISHERS	P=0.511N	P=0.408	P=0.322	P=0.595N
ORDER RESTRICTED	P=0.533	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.539	(e)	(e)	(e)

TDMS No. 97008-06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

PROPARGYL ALCOHOL

CAS Number: 107-19-7

Date Report Reqsted: 07/11/2006

Time Report Reqsted: 13:06:48

First Dose M/F: 09/17/01 / 09/17/01

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

Urinary Bladder  
Inflammation

LESION RATES

OVERALL (a)	0/50 (0%)	0/47 (0%)	0/48 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/45.42	0/43.88	0/41.96	0/43.70
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/39 (0%)	0/38 (0%)	0/32 (0%)	0/38 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

LIFE TABLE	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM
<b>Uterus Angiectasis</b>				
<b>LESION RATES</b>				
OVERALL (a)	2/50 (4%)	0/50 (0%)	2/50 (4%)	3/49 (6%)
POLY-3 RATE (b)	2/45.42	0/46.12	2/43.40	3/43.70
POLY-3 PERCENT (g)	4.4%	0%	4.6%	6.9%
TERMINAL (d)	2/39 (5%)	0/39 (0%)	1/32 (3%)	3/38 (8%)
FIRST INCIDENCE	731 (T)	---	664	731 (T)
<b>STATISTICAL TESTS</b>				
LIFE TABLE	P=0.225	P=0.238N	P=0.630	P=0.488
POLY 3	P=0.221	P=0.234N	P=0.678	P=0.482
POLY 1.5	P=0.221	P=0.234N	P=0.686	P=0.482
POLY 6	P=0.221	P=0.236N	P=0.665	P=0.482
LOGISTIC REGRESSION	P=0.221	(e)	P=0.676	P=0.488
COCH-ARM / FISHERS	P=0.230	P=0.247N	P=0.691N	P=0.490
ORDER RESTRICTED	P=0.200	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.211	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	8 PPM	16 PPM	32 PPM

Uterus: Endometrium  
Hyperplasia Cystic

**LESION RATES**

OVERALL (a)	6/50 (12%)	4/50 (8%)	1/50 (2%)	0/49 (0%)
POLY-3 RATE (b)	6/45.42	4/46.12	1/43.15	0/43.70
POLY-3 PERCENT (g)	13.2%	8.7%	2.3%	0%
TERMINAL (d)	6/39 (15%)	4/39 (10%)	1/32 (3%)	0/38 (0%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	---

**STATISTICAL TESTS**

LIFE TABLE	P=0.007N**	P=0.368N	P=0.094N	P=0.019N*
POLY 3	P=0.005N**	P=0.360N	P=0.064N	P=0.017N*
POLY 1.5	P=0.005N**	P=0.361N	P=0.060N	P=0.017N*
POLY 6	P=0.005N**	P=0.365N	P=0.071N	P=0.017N*
LOGISTIC REGRESSION	P=0.007N**	P=0.368N	P=0.094N	(e)
COCH-ARM / FISHERS	P=0.005N**	P=0.370N	P=0.056N	P=0.014N*
ORDER RESTRICTED	P=0.005N**	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.007N**	(e)	(e)	(e)

TDMS No. 97008-06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

PROPARGYL ALCOHOL

CAS Number: 107-19-7

Date Report Requested: 07/11/2006

Time Report Requested: 13:06:48

First Dose M/F: 09/17/01 / 09/17/01

Lab: BNW

**LEGEND**

- (a) Number of tumor-bearing animals/number of animals examined at site.
  - (b) Number of tumor-bearing animals/Poly-3 number
  - (d) Observed incidence at terminal kill.
  - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
  - (e) Value of Statistic cannot be computed.
  - (g) Poly-3 adjusted lifetime tumor incidence.
  - (I) Interim sacrifice
  - (T) Terminal sacrifice
  - # Tumor rates based on numbers of animals necropsied.
  - \* To the right of any statistical result, indicates significance at ( $P \leq 0.05$ ).
  - \*\* To the right of any statistical result, indicates significance at ( $P \leq 0.01$ ).
  - N Indicates a negative trend for all tests
- Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.  
The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

\*\*\* END OF REPORT \*\*\*